434 related articles for article (PubMed ID: 22031865)
1. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
Metzeler KH; Becker H; Maharry K; Radmacher MD; Kohlschmidt J; Mrózek K; Nicolet D; Whitman SP; Wu YZ; Schwind S; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
Blood; 2011 Dec; 118(26):6920-9. PubMed ID: 22031865
[TBL] [Abstract][Full Text] [Related]
2. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
3. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
4. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
[No Abstract] [Full Text] [Related]
7. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
Mrózek K; Marcucci G; Nicolet D; Maharry KS; Becker H; Whitman SP; Metzeler KH; Schwind S; Wu YZ; Kohlschmidt J; Pettenati MJ; Heerema NA; Block AW; Patil SR; Baer MR; Kolitz JE; Moore JO; Carroll AJ; Stone RM; Larson RA; Bloomfield CD
J Clin Oncol; 2012 Dec; 30(36):4515-23. PubMed ID: 22987078
[TBL] [Abstract][Full Text] [Related]
10. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
11. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
Verhaak RG; Goudswaard CS; van Putten W; Bijl MA; Sanders MA; Hugens W; Uitterlinden AG; Erpelinck CA; Delwel R; Löwenberg B; Valk PJ
Blood; 2005 Dec; 106(12):3747-54. PubMed ID: 16109776
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
[No Abstract] [Full Text] [Related]
13. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
[TBL] [Abstract][Full Text] [Related]
16. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
20. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]